Characterization of the immune response in the synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome

Rheumatology

Volumn 47, Issue 8, 2008, Pages 1160-1167

  Hurtado Nedelec, M ^a,b   Chollet Nartin, S ^a,b   Nicaise Roland, P ^a   Grootenboer Mignot, S ^a   Ruimy, R ^a   Meyer, O ^a   Hayem, Gilles ^a  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Innate immunity; Interleukin 8; Polymorphonuclear neutrophil; Propionibacterium acnes; SAPHO syndrome; Tumour necrosis factor

Indexed keywords

AUTOANTIBODY; CYTOKINE; ETANERCEPT; IMMUNOGLOBULIN; INTERLEUKIN 18; INTERLEUKIN 8; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; EX VIVO STUDY; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL PARAMETERS; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; PSORIATIC ARTHRITIS; RESPIRATORY BURST; RHEUMATOID ARTHRITIS; SAPHO SYNDROME;

ACQUIRED HYPEROSTOSIS SYNDROME; ADULT; AGED; ANTIGENS, BACTERIAL; ANTIRHEUMATIC AGENTS; AUTOANTIBODIES; C-REACTIVE PROTEIN; CELLS, CULTURED; CYTOKINES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS; INTERLEUKIN-18; INTERLEUKIN-8; MALE; MIDDLE AGED; NEUTROPHILS; PROPIONIBACTERIUM ACNES; REACTIVE OXYGEN SPECIES; RECEPTORS, TUMOR NECROSIS FACTOR; TETRADECANOYLPHORBOL ACETATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 47849112933     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken185     Document Type: Article

References (54)

1. Hayem G, Bouchaud-Chabot A, Benali K et al. SAPHO syndrome: A long-term follow-up study of 120 cases. Semin Arthritis Rheum 1999;29:159-71.
2. Van Doornum S, Barraclough D, McColl G, Wicks I. SAPHO: Rare or just not recognized? Semin Arthritis Rheum 2000;30:70-7.
3. Hayem G. Valuable lessons from SAPHO syndrome. Joint Bone Spine 2007;74:123-6.
4. Jansson A, Renner ED, Ramser J et al. Classification of non-bacterial osteitis: Retrospective study of clinical, immunological and genetic aspects in 89 patients. Rheumatology 2007;46:154-60.
5. Girschick HJ, Raab P, Surbaum S et al. Chronic non-bacterial osteomyelitis in children. Ann Rheum Dis 2005;64:279-85.
6. Chamot AM, Benhamou CL, Kahn MF, Beraneck L, Kaplan G, Prost A. Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey. 85 cases. Rev Rhum Mal Osteoartic 1987;54:187-96.
7. Benhamou CL, Chamot AM, Kahn MF. Synovitis-acne-pustulosis hyperostosis-osteomyelitis syndrome (SAPHO). A new syndrome among the spondyloarthropathies? Clin Exp Rheumatol 1988;6:109-12.
8. Byrd L, Grossmann M, Potter M, Shen-Ong GLC. Chronic multifocal osteomyelitis, a new recessive mutation on chromosome 18 of the mouse. Genomics 1991;11:794-8.
9. Golla A, Jansson A, Ramser J et al. Chronic recurrent multifocal osteomyelitis (CRMO): Evidence for a susceptibility gene located on chromosome 18q21.3-18q22. Eur J Hum Genet 2002;10:217-21.
10. Ferguson PJ, Bing X, Vasef MA et al. A missense mutation in pstpip2 is associated with the murine autoinflammatory disorder chronic multifocal osteomyelitis. Bone 2006;38:41-47.
11. Grosse J, Chitu V, Marquardt A et al. Mutation of mouse Mayp/ Pstpip2 causes a macrophage autoinflammatory disease. Blood 2006;107:3350-8.
12. Al-Mosawi ZS, Roya KKA-S, Ijadi-Maghsoodi R, El-Shanti HI, Ferguson PJ. A splice site mutation confirms the role of LPIN2 in Majeed syndrome. Arthritis Rheum 2007;56:960-4.
13. Kirchhoff T, Merkesdal S, Rosenthal H et al. Diagnostic management of patients with SAPHO syndrome: Use of MR imaging to guide bone biopsy at CT for microbiological and histological work-up. Eur Radiol 2003;13:2304-8.
14. Perry AL, Lambert PA. Propionibacterium acnes. Lett Appl Microbiol 2006;42:185-8.
15. Schaeverbeke T, Lequen L, de Barbeyrac B et al. Propionibacterium acnes isolated from synovial tissue and fluid in a patient with oligoarthritis associated with acne and pustulosis. Arthritis Rheum 1998;41:1889-93.
16. Rozin AP, Nahir AM. Is SAPHO syndrome a target for antibiotic therapy? Clin Rheumatol 2007;26:817-20.
17. Olivieri I, Padula A, Ciancio G, Salvarani C, Niccoli L, Cantini F. Successful treatment of SAPHO syndrome with infliximab: Report of two cases. Ann Rheum Dis 2002; 61:375-6.
18. Wagner AD, Andresen J, Jendro MC, Hulsemann JL, Zeidler H. Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum 2002;46:1965-8.
19. Carpenter E, Anne Jackson M, Friesen CA, Scarbrough M, Roberts CC. Crohn's-associated chronic recurrent multifocal osteomyelitis responsive to infliximab. J Pediatr 2004; 144:541-4.
20. Deutschmann A, Macho CJ, Bodo K, Zebedin D, Ring E. Successful treatment of chronic recurrent multifocal osteomyelitis with tumor necrosis factor-alpha blockage. Pediatrics 2005;116:1231-3.
21. Olivieri I, Padula A, Palazzi C. Pharmacological management of SAPHO syndrome. Expert Opin Invest Drugs 2006;15:1229-33.
22. Massara A, Cavazzini PL, Trotta F. In SAPHO syndrome anti-TNF-alpha therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations. Rheumatology 2006;45:730-3.
23. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
24. Taylor W, Gladman D, Helliwell P, Marchesoni A, Meese P, Mielants H. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
25. Grenier A, Dehoux M, Boutten A et al. Oncostatin M production and regulation by human polymorphonuclear neutrophils. Blood 1999;93:1413-21.
26. Grootenboer-Mignot S, Nicaise-Roland P, Delaunay C, Meyer O, Chollet-Martlin S, Labarre C. Second generation anti-cyclic citrullinated peptide (anti-CCP2) antibodies can replace other anti-filaggrin antibodies and improve rheumatoid arthritis diagnosis. Scand J Rheumatol 2004;33:218-20.
27. Sidiropoulos PI, Goulielmos G, Voloudakis GK, Petraki E, Boumpas DT. Inflammasome and rheumatic diseases: Evolving concepts. Ann Rheum Dis. Advance Access published October 5, 2007, doi: 0:ard.2007.078014v1.
28. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNFalpha and RANKL mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003;111:821-31.
29. Poubelle P, Chakravarti A, Fernandes M, Doiron K, Marceau A-A. Differential expression of RANK, RANK-L, and osteoprotegerin by synovial fluid neutrophils from patients with rheumatoid arthritis and by healthy human blood neutrophils. Arthritis Res Ther 2007;9:R25.
30. Klimiuk PA, Sierakowski S, Latosiewicz R et al. Circulating tumour necrosis factor alpha and soluble tumour necrosis factor receptors in patients with different patterns of rheumatoid synovitis. Ann Rheum Dis 2003;62:472-5.
31. Lee C-C, Lin W-Y, Wan L et al. Interleukin-18 gene polymorphism, but not interleukin-2 gene polymorphism, is associated with rheumatoid arthritis. Immunogenetics 2007;59:433-9.
32. Dai S-M, Shan Z-Z, Xu H, Nishioka K. Cellular targets of interleukin-18 in rheumatoid arthritis. Ann Rheum Dis 2007;66:1411-8.
33. Kuuliala K, Orpana A, Leirisalo-Repo M, Repo H. Neutrophils of healthy subjects with a history of reactive arthritis show enhanced responsiveness, as defined by CD11b expression in adherent and non-adherent whole blood cultures. Rheumatology 2007;46:934-7.
34. Scapini P, Lapinet-Vera JA, Gasperini S, Calzetti F, Bazzoni F, Cassatella MA. The neutrophil as a cellular source of chemokines. Immunol Rev 2000;177:195-203.
35. Lapinet JA, Scapini P, Calzetti F, Perez O, Cassatella MA. Gene expression and production of tumor necrosis factor alpha, interleukin-1 beta (IL-1beta), IL-8, macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, and gamma interferon-inducible protein 10 by human neutrophils stimulated with group B meningococcal outer membrane vesicles. Infect Immun 2000;68:6917-23.
36. Ethuin F, Delarche C, Benslama 8, Gougerot-Pocidalo M-A, Jacob L, Chollet-Martin S. Interleukin-12 increases interleukin 8 production and release by human polymorphonuclear neutrophils. J Leukoc Biol 2001;70:439-46.
37. Rossato M, Cencig S, Gasperini S, Cassatella MA, Bazzoni F. IL-10 modulates cytokine gene transcription by protein synthesis-independent and dependent mechanisms in lipopolysaccharide-treated noutrophils. Eur J Immunol 2007;37: 3176-89.
38. Kotilainen P, Merilahti-Palo R, Lehtonen OP et al. Propionibacterium acnes isolated. from sternal osteitis in a patient with SAPHO syndrome. J Rheumatol 1996;23: 1302-4.
39. Grassin Delyle L. Vittecoq O, Bourdel A, Duparc F, Michot C, Le Loot X. Chronic destructive oligoarthritis associated with Propionibacterium acnes in a female patient with acne vulgaris: Septic-reactive arthritis? Arthritis Rheum 2000;43:2843-7.
40. Chen Q, Koga T, Uchi H et al. Propionibacterium acnes-induced IL-8 production may be mediated by NF-kappaB activation in human monocytes. J Dermatol Sci 2002;29:97-103.
41. Nagy I, Pivarcsi A, Koreck A, Szell M, Urban E, Kemeny L. Distinct strains of Propionibacterium acnes induce selective human [beta]-helensin-2 and interleukin-8 expression in human keratinocytes through Toll-like receptors. J Investig Dermatol 2005;124:931-8.
42. Nagy I, Pivarcsi A, Kis K et al. Propionibacterium acnes and lipopolysaccharide induce the expression of antimicrobial peptides and proinflammatory cytokines/chemokines in human sebocytes. Microbes Infect 2006;8:2195-205.
43. Squaiella CC, Ananias RZ, Mussalem JS et al. In vivo and in vitro effect of killed Propionibacterium acnes and its purified soluble polysaccharide on mouse bone marrow stem cells and dendritic cell differentiation. Immunobiology 2006;211: 105-16.
44. Burkhart CN, Burkhart CG. Genome sequence of Propionibacterium acnes reveals immunogenic and surface-associated genes confirming existence of the acne biofilm. Int J Dermatol 2006;45:872.
45. Kermarrec N, Selloum S, Plantefeve G et al. Regulation of peritoneal and systemic neutorphil-derived tumor necrosis factor-alpha release in patients with severe peritonitis: Role of tumor necrosis factor-alpha converting enzyme cleavage. Crit Care Med 2005;33:1359-64.
46. Adib-Conquy M, Asehnoune K, Moine P, Cavaillon JM. Long-torm-impaired expression of nuclear factor-kappa B and I kappa B alpha in peripheral blood mononuclear cells of trauma patients. J Leukoc Biol 2001;70:30-8.
47. Carty SM, Snowden N, Silman AJ. Should infection still be considered as the most likely triggering factor for rheumatoid arthritis? Ann Rheum Dis 2004; 63(Suppl 2):iI46-9.
48. Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis 2003; 62:561-4.
49. Madhusudan S, Foster M, Muthuramalingam SR et al. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res 2004;10:6528-34.
50. Kast RE. Evidence of a mechanism by which etanercept increased TNF-alpha in multiple myeloma: New insights into the biology of TNF-alpha giving new treatment opportunities-the role of bupropion. Leuk Res 2005;29:1459-63.
51. Marotte H, Maslinski W, Miossec P. Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: Link to clinical response. Arthritis Res Thor 2005;7:R149-55.
52. Elbim C, Chollet-Martin S, Bailly S, Hakim J, Gougerot-Pocidalo MA. Priming of polymorphonuclear neutrophils by tumor necrosis factor alpha in whole blood: Identification of two polymorphonuclear neutrophil subpopulations in response to formy-peptides. Blood 1993;82:633-40.
53. Van den Berg JM, Weyer S, Weening JJ, Roos D, Kuijpers TW. Divergent effects of tumor necrosis factor alpha on apoptosis of human neutrophils. J Leukoc Biol 2001;69:467-73.
54. Cross A, Moots RJ, Edwards SW. The dual effects of TNFalpha on neutrophil apoptosis are mediated via differential effects on expression of Mcl-1 and Bfl-1. Blood 2008;111:878-84.